Glenmark Pharmaceuticals (BOM:532296) EPS (Basic) : ₹-53.22 (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals EPS (Basic)?

Glenmark Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was ₹-43.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-53.22.

Glenmark Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was ₹-43.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-53.22.

Glenmark Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was ₹-34.53. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -41.29.

During the past 12 months, Glenmark Pharmaceuticals's average EPS without NRIGrowth Rate was -470.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Glenmark Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 87.60% per year. The lowest was -21.40% per year. And the median was 6.50% per year.

Glenmark Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Glenmark Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals EPS (Basic) Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EPS (Basic)

Get a 7-Day Free Trial

27.50

34.38

33.37

10.53

-53.22

Glenmark Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-15.18	5.31	-2.90	-12.45	-43.18

Glenmark Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Glenmark Pharmaceuticals's Basic EPS for the fiscal year that ended in Mar. 2024 is calculated as

Basic EPS (A: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-15016.68	-	0)	/	282.162
	=	-53.22

Glenmark Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12182.82	-	0)	/	281.878
	=	-43.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-53.22

Glenmark Pharmaceuticals (BOM:532296) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Glenmark Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Glenmark Pharmaceuticals (BOM:532296) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » EPS (Basic)

Traded in Other Exchanges

GLENMARK:India

Address

Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines